Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Net Income (2021 - 2026)

Invivyd's (IVVD) quarterly Net Income came in at -$45.8 million in Q2 2026, down 204.25% on a YoY basis from $44.0 million in Q2 2025, and down 264.95% quarter-over-quarter from -$12.6 million in Q4 2025.

Analysis

Invivyd (IVVD) Net Income (2021 - 2026) Analysis & Trends

Invivyd (IVVD) has reported Net Income for 6 consecutive years, with -$45.8 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Net Income fell 204.25% year-over-year to -$45.8 million; the trailing twelve-month figure through Jun 2026 stood at -$84.5 million (up 25.6% YoY), and the FY2025 full-year result was -$55.6 million, up 68.59% from the prior year.
  • Net Income declined to -$45.8 million in Q2 2026 per IVVD's latest filing, from -$12.6 million in the prior quarter.
  • Across five years, Net Income topped out at -$11.0 million in Q3 2025 and bottomed at -$100.7 million in Q1 2022.
  • Historically, Net Income has averaged -$43.5 million across 5 years, with a median of -$46.1 million in 2024.
  • The sharpest annual moves came in 2025 and 2026: Net Income jumped 82.31% in 2025, then plunged 204.25% in 2026.
  • Over 5 years, Net Income stood at -$48.2 million in 2022, then sank by 59.2% to -$76.8 million in 2023, then surged by 74.95% to -$19.2 million in 2024, then surged by 34.71% to -$12.6 million in 2025, then plunged by 264.95% to -$45.8 million in 2026.
  • According to Business Quant data, Net Income over the past three periods registered -$45.8 million, -$12.6 million, and -$11.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 601.00 Mn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 164.49 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 97.50 Mn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn -13.27 Mn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn -45.82 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -45.82 Mn
Dec 31, 2025 -12.56 Mn
Sep 30, 2025 -11.02 Mn
Jun 30, 2025 -15.06 Mn
Mar 31, 2025 -16.92 Mn
Dec 31, 2024 -19.23 Mn
Sep 30, 2024 -62.31 Mn
Jun 30, 2024 -49.25 Mn
Mar 31, 2024 -46.09 Mn
Dec 31, 2023 -76.75 Mn
Sep 30, 2023 -43.06 Mn
Jun 30, 2023 -53.88 Mn
Mar 31, 2023 -39.07 Mn
Dec 31, 2022 -48.21 Mn
Sep 30, 2022 -47.33 Mn
Jun 30, 2022 -51.75 Mn
Mar 31, 2022 -100.74 Mn
Dec 31, 2021 -83.09 Mn
Sep 30, 2021 -60.37 Mn
Jun 30, 2021 -44.67 Mn